Wockhardt Ltd's Q3FY25 Quarter Results
- 08 Feb 2025
Result Summary
- Wockhardt Ltd reported a 10.9% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 2.8%.
- Its expenses for the quarter were down by 14.4% QoQ and 11.1% YoY.
- The net profit decreased 225.0% QoQ and decreased 123.3% YoY.
- The earnings per share (EPS) of Wockhardt Ltd stood at 0.9 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 729.00 | 818.00 | 709.00 | -10.9% | 2.8% |
Total Expenses | 708.00 | 827.00 | 796.00 | -14.4% | -11.1% |
Profit Before Tax | 21.00 | -9.00 | -87.00 | -333.3% | -124.1% |
Tax | 1.00 | 7.00 | -1.00 | -85.7% | -200.0% |
Profit After Tax | 20.00 | -16.00 | -86.00 | -225.0% | -123.3% |
Earnings Per Share | 0.90 | -1.50 | -5.80 | -160.0% | -115.5% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Wockhardt Ltd is an established pharmaceutical and biotechnology company that primarily operates in the healthcare industry. The company is known for manufacturing and marketing a broad range of pharmaceutical products, including generics, biosimilars, and over-the-counter medications. Wockhardt has a significant presence in the domestic as well as international markets, with a focus on research and development to foster innovation in its product offerings. While specific recent developments for Wockhardt are not detailed here, the company historically emphasizes advancements in its R&D capabilities and strategic partnerships to enhance its market position.
Revenue
In the third quarter of the fiscal year 2025 (Q3FY25), Wockhardt Ltd reported a total income of ₹729.00 crores. This represents a quarter-over-quarter (QoQ) decline of 10.9% from ₹818.00 crores in Q2FY25. However, there was a year-over-year (YoY) increase of 2.8% compared to ₹709.00 crores in Q3FY24. These figures suggest variations in revenue performance over the different periods analyzed. The fluctuations in total income over the quarters and the year indicate dynamic changes in the company's revenue generation capability within these periods.
Profitability
The profitability metrics for Wockhardt Ltd demonstrate a significant turnaround in Q3FY25. The company achieved a profit before tax (PBT) of ₹21.00 crores, compared to a loss of ₹9.00 crores in Q2FY25 and a more substantial loss of ₹87.00 crores in Q3FY24. This change signifies a QoQ improvement of 333.3% and a YoY improvement of 124.1%. Additionally, the profit after tax (PAT) stood at ₹20.00 crores in Q3FY25, marking a considerable improvement from a loss of ₹16.00 crores in Q2FY25 and a loss of ₹86.00 crores in Q3FY24. The earnings per share (EPS) was ₹0.90 in Q3FY25, compared to -₹1.50 in Q2FY25 and -₹5.80 in Q3FY24, reflecting an enhancement in shareholder value during the period.
Operating Metrics
Wockhardt Ltd's operating expenses showed a notable decrease in Q3FY25, with total expenses amounting to ₹708.00 crores, which is a 14.4% reduction from ₹827.00 crores in Q2FY25 and an 11.1% decrease from ₹796.00 crores in Q3FY24. This reduction in expenses contributes to the company's improved profitability metrics observed in the same period. The tax expenditure in Q3FY25 was ₹1.00 crore, which is a decrease from ₹7.00 crores in Q2FY25, and a change from a tax credit of -₹1.00 crore in Q3FY24. These operating metrics provide insights into the company's cost management and tax liability impact on its financial results.
